Jian Xie
Net Worth
Last updated:
What is Jian Xie net worth?
The estimated net worth of Mr. Jian Xie is at least $18,624,265 as of 3 Dec 2024. He owns shares worth $7,219,069 as insider, has earned $10,282,496 from insider trading and has received compensation worth at least $1,122,700 in Fulgent Genetics, Inc..
What is the salary of Jian Xie?
Mr. Jian Xie salary is $224,540 per year as Chief Operating Officer in Fulgent Genetics, Inc..
How old is Jian Xie?
Mr. Jian Xie is 59 years old, born in 1966.
What stocks does Jian Xie currently own?
As insider, Mr. Jian Xie owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | Chief Operating Officer | 334,681 | $21.57 | $7,219,069 |
What does Fulgent Genetics, Inc. do?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Jian Xie insider trading
Fulgent Genetics, Inc.
Mr. Jian Xie has made 41 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,455 units of FLGT stock worth $28,373 on 3 Dec 2024.
The largest trade he's ever made was exercising 62,000 units of FLGT stock on 9 Mar 2021. As of 3 Dec 2024 he still owns at least 334,681 units of FLGT stock.
Fulgent Genetics key executives
Fulgent Genetics, Inc. executives and other stock owners filed with the SEC:
- Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. (58) Chief Scientific Officer & Laboratory Director
- Mr. Jian Xie (59) Chief Operating Officer
- Mr. Ming Hsieh (69) Chairman, Chief Executive Officer & Pres
- Mr. Paul Kim (58) Chief Financial Officer